Edition:
United States

Eisai Co Ltd (ESALY.PK)

ESALY.PK on OTC Markets Group

53.63USD
1:04pm EDT
Change (% chg)

$0.39 (+0.73%)
Prev Close
$53.24
Open
$53.43
Day's High
$53.75
Day's Low
$53.43
Volume
2,935
Avg. Vol
6,696
52-wk High
$66.92
52-wk Low
$53.24

ESALY.PK

Chart for ESALY.PK

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's businesses include pharmaceutical business and other business. The Company's segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South... (more)

Overall

Beta: -0.19
Market Cap(Mil.): $15,796.02
Shares Outstanding(Mil.): 296.57
Dividend: 0.63
Yield (%): 2.56

Financials

  ESALY.PK Industry Sector
P/E (TTM): 51.25 28.87 29.63
EPS (TTM): 1.04 -- --
ROI: 4.37 13.48 13.01
ROE: 6.74 14.39 14.16

BRIEF-Positive topline results show Eisai's Lenvatinib meets primary endpoint

* Positive topline results of large phase 3 trial show Eisai's lenvatinib meets primary endpoint in unresectable hepatocellular carcinoma

Jan 25 2017

Swiss stocks - Factors to watch on Jan 16

ZURICH, Jan 16 The Swiss blue-chip SMI was seen opening 0.2 percent easier at 8,436 points on Monday, according to premarket indications by bank Julius Baer .

Jan 16 2017

Halozyme's pancreatic cancer drug succeeds in mid-stage trial

Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.

Jan 05 2017

BRIEF-Eisai Co says FDA grants fast track designation for development of E2609

* Eisai inc - first phase 3 study for e2609 in clinical trial program will enroll 1,330 patients with biomarkers confirmed for early alzheimer's disease

Nov 17 2016

Eisai latest cancer drugmaker to win UK approval after price cut

LONDON Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.

Nov 02 2016

Eisai latest cancer drugmaker to win UK approval after price cut

LONDON, Nov 3 Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.

Nov 02 2016

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.58 +0.32
GlaxoSmithKline plc (GSK.L) 1,675.00 +4.50
Novartis AG (NOVN.S) CHF74.15 +0.75
Merck & Co., Inc. (MRK.N) $63.49 -0.01
AstraZeneca plc (AZN.L) 4,959.50 +107.00
Pfizer Inc. (PFE.N) $34.44 -0.03
Bristol-Myers Squibb Co (BMY.N) $56.00 -0.36
Bristol-Myers Squibb Co (BMYMP.PK) $1,050.00 --
Sanofi SA (SASY.PA) €83.30 +0.53
Roche Holding Ltd. (ROG.S) CHF252.60 +2.40

Earnings vs. Estimates